title: Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
authors.forename: T
authors.initials: T
authors.lastname: Elter
authors.forename: R
authors.initials: R
authors.lastname: James
authors.forename: R
authors.initials: R
authors.lastname: Busch
authors.forename: D
authors.initials: D
authors.lastname: Winkler
authors.forename: M
authors.initials: M
authors.lastname: Ritgen
authors.forename: S
authors.initials: S
authors.lastname: Böttcher
authors.forename: C
authors.initials: C
authors.lastname: Kahl
authors.forename: W
authors.initials: W
authors.lastname: Gassmann
authors.forename: M
authors.initials: M
authors.lastname: Stauch
authors.forename: I
authors.initials: I
authors.lastname: Hasan
authors.forename: P
authors.initials: P
authors.lastname: Staib
authors.forename: K
authors.initials: K
authors.lastname: Fischer
authors.forename: A-M
authors.initials: AM
authors.lastname: Fink
authors.forename: J
authors.initials: J
authors.lastname: Bahlo
authors.forename: A
authors.initials: A
authors.lastname: Bühler
authors.forename: H
authors.initials: H
authors.lastname: Döhner
authors.forename: C-M
authors.initials: CM
authors.lastname: Wendtner
authors.forename: S
authors.initials: S
authors.lastname: Stilgenbauer
authors.forename: A
authors.initials: A
authors.lastname: Engert
authors.forename: M
authors.initials: M
authors.lastname: Hallek
mesh_terms: D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D016879:Salvage Therapy; D015996:Survival Rate; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074323:Alemtuzumab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine